Bausch Health (English Wikipedia)

"Valeant Pharmaceuticals Subpeonaed In U.S. After Price-Gouging Allegations". New York: The Huffington Post via The Canadian Press and the Associated Press. October 15, 2015. Retrieved October 15, 2015.

institutionalinvestor.com

Hacked Printers. Fake Emails. Questionable Friends. Fahmi Quadir Was Up 24% Last Year, But It Came at a Price. Institutional Investor, 9 January 2019

labusinessjournal.com

"Panic Gone, New ICN Team Finds Finances in Disarray". Los Angeles Business Journal. 29 July 2002. Archived from the original on 11 January 2018. Retrieved 10 January 2018.

nasdaq.com

"This Bausch Health Companies Unusually Active Option Is a No-Brainer". NASDAQ. Archived from the original on 2024-03-31. Retrieved 2024-03-31.

nytimes.com

"Shareholders Approve ICN Pharmaceuticals Merger". The New York Times. November 3, 1994.
Pollack, Andrew; Tavernise, Sabrina (October 4, 2015). "Valeant's Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers". The New York Times. ISSN 0362-4331. Retrieved October 4, 2015.
Pollack, Andrew (September 20, 2015). "Drug Goes From $13.50 a Tablet to $750, Overnight". The New York Times. Retrieved October 15, 2015.
Morgenson, Gretchen (October 2, 2015). "Valeant's High-Price Drug Strategy". The New York Times. Retrieved October 2, 2015.
Alexandra Stevenson; Matthew Goldstein (April 27, 2016), "As Valeant Tumbles, So Does Bill Ackman's Hedge Fund Herd", The New York Times, retrieved April 28, 2016
"Bausch Health Plans $1.21 B Settlement Over Stock Plunge". The New York Times. Associated Press. 2019-12-16. ISSN 0362-4331. Retrieved 2019-12-16.

dealbook.nytimes.com

David Gelles (November 17, 2014). "Allergan Escapes Valeant's Pursuit, Agreeing to Be Bought by Actavis". The New York Times.

ocregister.com

"Allergan Fight Conjures Ghost of O.C.'s Past". The Orange County Register. 19 May 2014.

pressreader.com

van der Linde, Damon (October 22, 2015). "Valeant stocks plunge, trading halted". Calgary Herald. Retrieved October 22, 2015.
Van der Linde, Damon (16 October 2015). "Valeant Pharmaceuticals pricing controversy attracts scrutiny". Calgary Herald. Retrieved 16 October 2015.

prnewswire.com

"ICN Pharmaceuticals, Inc. Changes Its Name To Valeant Pharmaceuticals International" (Press release). PRNewswire. November 12, 2003. Archived from the original on April 9, 2016. Retrieved March 28, 2016.
"Valeant to Acquire Tecnofarma, A Mexican Generic Company" (Press release). PRNewswire. July 29, 2009. Archived from the original on April 5, 2016. Retrieved March 23, 2016.
"Valeant to Acquire Laboratoire Dr. Renaud in Canada" (Press release). PRNewswire. December 7, 2009. Archived from the original on April 5, 2016. Retrieved March 23, 2016.
"Valeant to Acquire Branded Generics/OTC Company in Brazil" (Press release). PRNewswire. March 19, 2010.
"Valeant to Acquire Vital Science Corp. in Canada" (Press release). April 28, 2010.
"Valeant Pharmaceuticals Completes Acquisition of Aton Pharma, Inc" (Press release). PRNewswire. May 27, 2010.
"Valeant and Biovail Complete Merger" (Press release). PRNewswire. September 28, 2010.
"Valeant Pharmaceuticals to Acquire PharmaSwiss S.A." (Press release). PR Newswire. February 1, 2011.
"Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Atlantis Pharma in Mexico" (Press release). PR Newswire. April 18, 2012.
"Valeant Pharmaceuticals Agrees to Acquire Sanitas Group for Approximately EUR314 Million in Cash" (Press release). PR Newswire. May 24, 2011. Retrieved October 7, 2014.
"Valeant Pharmaceuticals Agrees to Acquire iNova" (Press release). PR Newswire. November 20, 2011. Retrieved October 7, 2014.
"Valeant Pharmaceuticals Completes Acquisition of Dermik" (Press release). PR Newswire. December 19, 2011. Retrieved October 7, 2014.
"Valeant Pharmaceuticals Acquires Probiotica in Brazil" (Press release). PR Newswire. February 1, 2012. Retrieved October 7, 2014.
"Valeant Pharmaceuticals to Acquire Eyetech" (Press release). PR Newswire. February 13, 2012. Retrieved October 7, 2014.
"Valeant Pharmaceuticals to Acquire Pedinol" (Press release). PR Newswire. April 12, 2012. Retrieved October 7, 2014.
"Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Atlantis Pharma in Mexico" (Press release). PR Newswire. April 18, 2012.
"Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical" (Press release). PR Newswire. May 3, 2012.
"Valeant Pharmaceuticals Agrees To Acquire OraPharma" (Press release). PR Newswire. June 15, 2012. Retrieved October 7, 2014.
"Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash" (Press release). PR Newswire. September 3, 2012.
"Valeant Completes Acquisition Of Natur Produkt In Russia" (Press release). PR Newswire. February 1, 2013. Retrieved October 7, 2014.
"Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash" (Press release). PR Newswire. March 20, 2013. Retrieved October 7, 2014.
"Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For $8.7 Billion" (Press release). PR Newswire. May 27, 2013.
"Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Solta Medical, Inc" (Press release). PRNewswire. January 23, 2014.
"Valeant Pharmaceuticals Completes Acquisition Of PreCision Dermatology" (Press release). PRNewswire. July 8, 2014.
"Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd" (Press release). PRNewswire. April 1, 2015.
"Valeant Pharmaceuticals Agrees To Acquire Amoun Pharmaceutical" (Press release). PRNewswire. July 17, 2015.
"Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals" (Press release). PRNewswire. August 20, 2015.
"Valeant Pharmaceuticals To Acquire Synergetics USA" (Press release). PRNewswire. September 2, 2015.
"Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For $1.3 Billion" (Press release). PRNewswire. January 10, 2017.
"Sanpower Group Agrees to Acquire Dendreon From Valeant for $819.9 Million" (Press release). PRNewswire. January 10, 2017.

propublica.org

Ornstein, Charles (October 27, 2015). "Federal Investigators Looking at Valeant's Contact Lens Dealings". ProPublica.

reuters.com

"UPDATE 1-Valeant Q1 profit beats Street; to acquire Aton Pharma". Reuters. May 3, 2010.
"Drugmaker Biovail to buy Valeant in $3.3 billion deal". Reuters. June 21, 2010. Archived from the original on October 6, 2015. Retrieved July 3, 2017.
Carl O'Donnell (October 29, 2015). "Valeant's ambitious plan for its contact lens business". Reuters.
Euan Rocha (February 4, 2014). "Valeant to buy PreCision Dermatology for $475 million". Reuters. Archived from the original on November 2, 2015. Retrieved July 3, 2017.
"Drugmaker Valeant completes $11 billion purchase of Salix". Reuters. 2015-04-01. Retrieved 2020-04-28.
Beasley, Deena (January 28, 2016). "Clinton targets Valeant price hikes in campaign appearance". Reuters. Retrieved July 17, 2016.
Pierson, Brendan (May 29, 2020). "CORRECTED: Special master says he will approve $1.21 bln Bausch securities settlement". Reuters – via www.reuters.com.
"Bausch Health agrees to pay $1.21 billion to settle share price lawsuit". Reuters. 2019-12-16. Retrieved 2019-12-16.

uk.reuters.com

Grover, Divya (10 August 2023). "Valeant looks to trim debt pile with $930 million iNova sale". Archived from the original on June 9, 2017.
Editorial, Reuters (10 August 2023). "Valeant to sell Obagi Medical Products business for $190 million". Archived from the original on July 18, 2017. {{cite web}}: |first= has generic name (help)
Editorial, Reuters. "Valeant to sell female libido pill business back to former owners". reuters.com. Archived from the original on November 6, 2017. Retrieved 7 April 2018. {{cite web}}: |first= has generic name (help)

sec.gov

"Pharmaceutical Company and Former Executives Charged With Misleading Financial Disclosures". Retrieved 14 June 2021.
"US SEC: Form 10-K Valeant Pharmaceuticals International, Inc". U.S. Securities and Exchange Commission. Retrieved March 4, 2018.

senate.gov

aging.senate.gov

"Valeant Pharmaceuticals' Business Model: the Repercussions for Patients and the Health Care System", United States Senate Special Committee on Aging, April 27, 2016, retrieved April 29, 2016

thestreet.com

Elizabeth Gurdus (10 January 2017). "Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'". The Street.

tipranks.com

"Salix Pharmaceuticals announces Phase 2 investigator-initiated study of RELISTOR". Tipranks. Archived from the original on 2024-03-31. Retrieved 2024-03-31.

valeant.com

ir.valeant.com

"Valeant Agrees To Sell Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals". ir.valeant.com. Retrieved 7 April 2018.

valeantsecuritiessettlement.com

"NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION" (PDF). Valeant Securities Settlement. 2020-01-23. Retrieved 2023-12-16.

web.archive.org

"Panic Gone, New ICN Team Finds Finances in Disarray". Los Angeles Business Journal. 29 July 2002. Archived from the original on 11 January 2018. Retrieved 10 January 2018.
"ICN Pharmaceuticals, Inc. Changes Its Name To Valeant Pharmaceuticals International" (Press release). PRNewswire. November 12, 2003. Archived from the original on April 9, 2016. Retrieved March 28, 2016.
"Sweden's Meda AB Buys American Valeant Pharmaceuticals International Units for 392 Million" (Press release). Business Wire. August 4, 2008. Archived from the original on October 11, 2014. Retrieved October 7, 2014.
"Valeant to Acquire Tecnofarma, A Mexican Generic Company" (Press release). PRNewswire. July 29, 2009. Archived from the original on April 5, 2016. Retrieved March 23, 2016.
"Valeant to Acquire Laboratoire Dr. Renaud in Canada" (Press release). PRNewswire. December 7, 2009. Archived from the original on April 5, 2016. Retrieved March 23, 2016.
"Drugmaker Biovail to buy Valeant in $3.3 billion deal". Reuters. June 21, 2010. Archived from the original on October 6, 2015. Retrieved July 3, 2017.
Euan Rocha (February 4, 2014). "Valeant to buy PreCision Dermatology for $475 million". Reuters. Archived from the original on November 2, 2015. Retrieved July 3, 2017.
Grover, Divya (10 August 2023). "Valeant looks to trim debt pile with $930 million iNova sale". Archived from the original on June 9, 2017.
Editorial, Reuters (10 August 2023). "Valeant to sell Obagi Medical Products business for $190 million". Archived from the original on July 18, 2017. {{cite web}}: |first= has generic name (help)
Editorial, Reuters. "Valeant to sell female libido pill business back to former owners". reuters.com. Archived from the original on November 6, 2017. Retrieved 7 April 2018. {{cite web}}: |first= has generic name (help)
"This Bausch Health Companies Unusually Active Option Is a No-Brainer". NASDAQ. Archived from the original on 2024-03-31. Retrieved 2024-03-31.
"Salix Pharmaceuticals announces Phase 2 investigator-initiated study of RELISTOR". Tipranks. Archived from the original on 2024-03-31. Retrieved 2024-03-31.

worldcat.org

search.worldcat.org

Pollack, Andrew; Tavernise, Sabrina (October 4, 2015). "Valeant's Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers". The New York Times. ISSN 0362-4331. Retrieved October 4, 2015.
Rockoff, Jonathan D.; Whalen, Jeanne. "Valeant and Pharmacy More Intertwined Than Thought". Wall Street Journal. ISSN 0099-9660. Retrieved October 10, 2015.(subscription required)
"Bausch Health Plans $1.21 B Settlement Over Stock Plunge". The New York Times. Associated Press. 2019-12-16. ISSN 0362-4331. Retrieved 2019-12-16.

wsj.com

Rockoff, Jonathan (20 August 2015). "Valeant to Buy Maker of Women's Libido Drug for $1 Billion". The Wall Street Journal. Retrieved 20 August 2015.
Rockoff, Jonathan D.; Whalen, Jeanne. "Valeant and Pharmacy More Intertwined Than Thought". Wall Street Journal. ISSN 0099-9660. Retrieved October 10, 2015.(subscription required)
Jonathan D. Rockoff (January 20, 2016). "Valeant Pharmaceutical Interim CEO to Testify Before Congress Next Week". WSJ.

yahoo.com

finance.yahoo.com

Andrew Steele (25 April 2016). "Valeant Pharma (VRX) Names Former Perrigo (PRGO) CEO to Fill Position". Yahoo Finance.
"Bausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite Vision Enhancement System". Yahoo Finance. 8 January 2017.
"John Paulson Joins Valeant Board Of Directors". Yahoo Finance. Retrieved 27 September 2017.